New SPECT scans could spot aggressive breast cancer without biopsy
NCT ID NCT05376644
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study tests two new radioactive imaging agents, 99mTc-ADAPT6 and 99mTc-DARPinG3, to see how well they can detect HER2-positive breast cancer using SPECT scans. Fifteen women with HER2-positive breast cancer will receive injections of each agent a few days apart, followed by imaging. The goal is to compare the imaging results with standard biopsy tests to determine if these agents can accurately identify HER2 status non-invasively before chemotherapy or targeted therapy begins.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 99mTc-ADAPT6 and 99mTc-DARPinG3
- What this could lead to
- If successful, these imaging agents could provide a non-invasive way to detect HER2-positive breast cancer, potentially guiding treatment decisions without needing a biopsy.
- What could go wrong
- This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The imaging agents are experimental and their accuracy compared to standard methods is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tomsk NRMC
Tomsk, 634005, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can early sexual health counseling transform breast cancer recovery?
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer